恩利文治療公司
US ˙ NasdaqGS ˙ US29337E1029

SecurityELVN / Enliven Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership69,875 shares
Latest Disclosed Value $ 1,076,074
Barclays Plc reports 1.15% decrease in ownership of ELVN / Enliven Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 69,875 shares of Enliven Therapeutics, Inc. (US:ELVN) valued at $1,076,075 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 70,689 shares of Enliven Therapeutics, Inc.. This represents a change in shares of -1.15% during the quarter. The current value of the position is $2,479,864 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F ENLIVEN THERAPEUTICS COM 29337E102 69,875 -814 -1.15 1,076 -25.64 0.0003
2026-03-31 2025-09-30 13F/A-3 ENLIVEN THERAPEUTICS COM 29337E102 70,689 -2,095 -2.88 1,447 -0.89 0.0003
2026-03-19 2025-09-30 13F/A-2 ENLIVEN THERAPEUTICS COM 29337E102 56,217 -16,567 1,436 0.0004
2025-11-12 2025-09-30 13F ENLIVEN THERAPEUTICS COM 29337E102 70,689 -2,095 1,447 0.0003
2026-02-27 2025-06-30 13F/A-2 ENLIVEN THERAPEUTICS COM 29337E102 72,784 22,427 44.54 1,460 47.33 0.0003
2025-08-14 2025-06-30 13F/A-1 ENLIVEN THERAPEUTICS COM 29337E102 72,784 22,427 1 0.0003
2025-08-13 2025-06-30 13F ENLIVEN THERAPEUTICS COM 29337E102 72,784 22,427 1 0.0001
2026-03-17 2025-03-31 13F/A-1 ENLIVEN THERAPEUTICS COM 29337E102 50,357 -14,206 -22.00 991 -31.75 0.0003
2025-05-15 2025-03-31 13F ENLIVEN THERAPEUTICS COM 29337E102 50,357 -14,206 1 0.0003
2026-03-19 2024-12-31 13F/A-1 ENLIVEN THERAPEUTICS COM 29337E102 64,563 8,346 14.85 1,453 1.18 0.0004
2025-02-13 2024-12-31 13F ENLIVEN THERAPEUTICS COM 29337E102 64,563 8,346 1 0.0004
2026-03-31 2024-09-30 13F/A-2 ENLIVEN THERAPEUTICS COM 29337E102 56,217 42,012 295.76 1,436 333.53 0.0004
2024-11-19 2024-09-30 13F/A-1 ENLIVEN THERAPEUTICS COM 29337E102 56,217 42,012 1 0.0004
2024-11-15 2024-09-30 13F ENLIVEN THERAPEUTICS COM 29337E102 56,217 42,012 1 0.0001
2026-03-23 2024-06-30 13F/A-1 ENLIVEN THERAPEUTICS COM 29337E102 14,205 -12,031 -45.86 332 -28.20 0.0001
2024-08-14 2024-06-30 13F ENLIVEN THERAPEUTICS COM 29337E102 14,205 -12,031 0 0.0001
2026-03-24 2024-03-31 13F/A-1 ENLIVEN THERAPEUTICS COM 29337E102 26,236 -15,842 -37.65 461 -20.79 0.0002
2024-05-15 2024-03-31 13F ENLIVEN THERAPEUTICS COM 29337E102 26,236 -15,842 0 0.0002
2026-03-25 2023-12-31 13F/A-1 ENLIVEN THERAPEUTICS COM 29337E102 42,078 28,449 208.74 582 212.90 0.0002
2024-02-15 2023-12-31 13F ENLIVEN THERAPEUTICS COM 29337E102 42,078 28,449 1 0.0002
2026-03-26 2023-09-30 13F/A-1 ENLIVEN THERAPEUTICS COM 29337E102 13,629 -1,198 -8.08 186 -38.41 0.0001
2023-11-07 2023-09-30 13F ENLIVEN THERAPEUTICS COM 29337E102 13,629 -1,198 0 0.0001
2026-03-30 2023-06-30 13F/A-2 ENLIVEN THERAPEUTICS COM 29337E102 14,827 7,600 105.16 303 91.14 0.0002
2023-09-20 2023-06-30 13F/A-1 ENLIVEN THERAPEUTICS COM 29337E102 14,827 7,600 0 0.0002
2023-08-03 2023-06-30 13F ENLIVEN THERAPEUTICS COM 29337E102 14,827 7,600 0 0.0002
2026-03-30 2023-03-31 13F/A-1 ENLIVEN THERAPEUTICS COM 29337E102 7,227 7,227 158 0.0001
2023-05-04 2023-03-31 13F ENLIVEN THERAPEUTICS COM 29337E102 7,227 7,227 0 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.